ArticleNature communications2025
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomaterial-driven regenerative drug delivery: a vicennial bibliometric landscape.Frontiers in medicine · 2025Pooled it
- An ultrasound-responsive hydrogel with piezoelectric-enhanced bioelectric-vesicular coupling alleviates mitochondrial dysfunction and inflammation for osteoarthritis therapy.Bioactive materials · 2027Article
- Quadruplex Bioactive FAND for Treating Acute Liver Failure Induced by Acetaminophen or Hepatectomy.Exploration (Beijing, China) · 2026Article
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
- Vitamin A-coupled MSCs- derived extracellular vesicles relieve acute liver injury by targeting hepatic stellate cells to deliver REDD1.Journal of nanobiotechnology · 2026Article
- Seminiferous tubule-inspired coaxial bioprinting-derived extracellular vesicles restore Leydig cell steroidogenesis through modulation of Wnt4/β-catenin signaling.Journal of nanobiotechnology · 2026Article
- Tuning mechanical softness as a design principle in drug delivery: A biomechanical perspective.Acta pharmaceutica Sinica. B · 2026Review
- Targeted delivery of berberineNanoscale advances · 2026Article
- 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026Review
- Article
- Engineered mesenchymal stem cell-derived exosomes: A revolutionary approach to unlocking liver disease treatment.Biochemistry and biophysics reports · 2025Review
- Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions.Bioengineering (Basel, Switzerland) · 2025Review
- Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms.Small science · 2025Review
- Identification of key biomarkers associated with necroptosis and immune infiltration in hepatitis B virus-related acute-on-chronic liver failure.Scientific reports · 2025Article
- Dual-ligand engineered exosome regulates WNT signaling activation to promote liver repair and regeneration.Nature communications · 2025Article
- MicroRNAs won the Nobel Prize. Now, can extracellular vesicles help them become drugs?Extracellular vesicle · 2025Article
- Exosome-based modulation of ferroptosis in neurological disorders: mechanisms, therapeutic potential, and translational challenges.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute liver failure (ALF) is a life-threatening condition caused by rapid hepatocyte death and impaired liver regeneration. Here we show that extracellular vesicles engineered to express Signal Regulatory Protein Alpha (SIRP-EVs), produced via a scalable 3D bioreactor process with high yield and purity, exhibit significant therapeutic potential by targeting damaged cells and promoting tissue repair. SIRP-EVs block CD47, a crucial inhibitory signal on necroptotic cells, to enhance macrophage-mediated clearance of dying hepatocytes. They also deliver regenerative cargo from mesenchymal stem cells, reprogramming macrophages to support liver regeneration. In male animal models, SIRP-EVs significantly reduce liver injury markers and improve survival, demonstrating their dual-function therapeutic efficacy. By integrating the resolution of necroptosis with regenerative macrophage reprogramming, SIRP-EVs represent a promising platform for restoring liver function. These findings support the development of EV-based in vivo macrophage reprogramming therapies for ALF and other inflammation-driven diseases, paving the way for the clinical application of engineered EV therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.